INFOGRAPHIC: High-Risk HR+, HER2- EBC: Carryover Effect of Oral Endocrine Therapy
As healthcare providers, it is important to understand the carry over effect of endocrine therapy for patients with HR+ EBC to develop an individualized treatment plan.
Date of Last Review: February 22, 2024
Are you satisfied with this content?